DRMA - Total Utang marang Modal Dermata Corp

Dermata Therapeutics (DRMA) is developing innovative treatments for rosacea and acne, leveraging a unique component delivery system to enhance therapy. Asset value growth is driven by the success of the DMT310 drug in late-stage trials and the prospects of licensing deals with industry behemoths. This price action reflects a debt-to-equity ratio of 0.00. A minimal environmental footprint achieved through production outsourcing supports the sustainability of the model.

By utilizing external CROs for acne clinical trials while maintaining control over patents, Dermata Therapeutics (DRMA) is able to optimize capital expenditures, which is directly reflected in the dynamics of the debt-to-equity ratio. This metric measures the proportion of borrowed funds relative to owner assets, demonstrating the degree of financial leverage and the company's resilience to credit risks over the long term.